| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 143, 845-856, Copyright © 1993 by American Society for Investigative Pathology
REGULAR ARTICLES |
E Cesarman, G Inghirami, A Chadburn and DM Knowles
Division of Surgical Pathology, Columbia University, College of Physicians and Surgeons, New York, New York 10032.
Strong immunohistochemical reactivity for p53 tumor suppressor gene product has been reported in a variety of different human malignancies including CD30- (Ki-1) positive anaplastic large cell lymphoma (ALCL). Although high levels of p53 protein have been interpreted as abnormal, rapidly proliferating benign and neoplastic lymphoid cells may have increased p53 expression in the absence of structural alterations. On the other hand, mutations in the p53 gene can lead to a lack of p53 protein production. Structural alterations of the p53 gene have not been documented in cases of ALCL and the mechanism for an abnormal pattern of p53 expression in these lymphomas has not been elucidated. Therefore, to determine whether an altered pattern of p53 expression correlates with mutations in the p53 locus in ALCL, we analyzed the expression of p53 protein immunohistochemically, compared it with the proliferation index using monoclonal antibody Ki-67, and assessed the presence of mutations in exons 5 though 9 of the p53 gene using a single-strand conformation polymorphism assay in a panel of 17 ALCLs. Furthermore, we studied the presence of allelic deletions of chromosome 17p by restriction fragment length polymorphism analysis. We found significant levels of p53 protein expression in 12 of the 15 cases studied, but identified mutations in only one of 17 cases. An allelic deletion in chromosome 17p was identified only in the one case containing a mutated p53 gene. Whereas the case containing structural alterations in the p53 gene did have strong p53 immunoreactivity, 11 cases that lacked p53 mutations in the regions examined also had significant levels of p53. Thus, our studies indicate that strong immunohistochemical reactivity for p53 is not a reliable indicator of the presence of structural alterations of p53 gene exons 5 through 9 in ALCL.
This article has been cited by other articles:
 |
|
 |
|
  K. H. Young, D. D. Weisenburger, B. J. Dave, L. Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. D. Gascoyne, G. Ott, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma Blood, December 15, 2007; 110(13): 4396 - 4405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sotlar, L. Escribano, O. Landt, S. Mohrle, S. Herrero, A. Torrelo, U. Lass, H.-P. Horny, and B. Bultmann One-Step Detection of c-kit Point Mutations Using Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping and Hybridization Probes Am. J. Pathol., March 1, 2003; 162(3): 737 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cordone, S. Masi, F. R. Mauro, S. Soddu, O. Morsilli, T. Valentini, M. L. Vegna, C. Guglielmi, F. Mancini, S. Giuliacci, et al. p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis Blood, June 1, 1998; 91(11): 4342 - 4349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Maestro, A. Gloghini, C. Doglioni, S. Piccinin, T. Vukosavljevic, D. Gasparotto, A. Carbone, and M. Boiocchi Human Non-Hodgkin's Lymphomas Overexpress a Wild-Type Form of p53 Which Is a Functional Transcriptional Activator of the Cyclin-Dependent Kinase Inhibitor p21 Blood, April 1, 1997; 89(7): 2523 - 2528. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
